The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

European Journal of Surgical Oncology

Volumn 41, Issue 8, 2015, Pages 1097-1105

  Kusamura, S ^a   Baratti, D ^a   Hutanu, I ^b   Gavazzi, C ^a   Morelli, D ^a   Iusco, D R ^c   Grassi, A ^c   Bonomi, S ^c   Virzi S ^c   Haeusler, E ^a   Deraco, M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Ospedale di Bentivoglio   (Italy)

Author keywords

Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Inflammation based scores; Prognosis; Pseudomyxoma peritonei

Indexed keywords

ALBUMIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; MITOMYCIN; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CYTOREDUCTIVE SURGERY; ENTERIC FEEDING; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INFLAMMATION; INTERMEDIATE RISK POPULATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; TOTAL PARENTERAL NUTRITION; BLOOD; EPIDEMIOLOGY; HYPERTHERMIC THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; ITALY; MORTALITY; MULTIMODALITY CANCER THERAPY; PERITONEAL NEOPLASMS; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PSEUDOMYXOMA PERITONEI; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TRENDS;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOREDUCTION SURGICAL PROCEDURES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INJECTIONS, INTRAPERITONEAL; ITALY; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PSEUDOMYXOMA PERITONEI; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84943375831     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.04.005     Document Type: Article

References (30)

1. R.M. Smeenk, M.L. van Velthuysen, V.J. Verwaal, and F.A. Zoetmulder Appendiceal neoplasms and pseudomyxoma peritonei: a population based study Eur J Surg Oncol 34 2 2008 Feb 196 201
2. T.C. Chua, B.J. Moran, P.H. Sugarbaker, and et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy J Clin Oncol 30 20 2012 Jul 10 2449 2456
3. D. Elias, F. Gilly, F. Quenet, and et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy Eur J Surg Oncol 36 5 2010 May 456 462
4. S. Kusamura, I. Hutanu, D. Baratti, and M. Deraco Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei J Surg Oncol 108 1 2013 Jul 1 8
5. J.M. Logan-Collins, A.M. Lowy, T.M. Robinson-Smith, and et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon Ann Surg Oncol 15 3 2008 Mar 738 744
6. E. Canbay, H. Ishibashi, S. Sako, and et al. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy World J Surg 37 6 2013 Jun 1271 1276
7. T.C. Chua, C.H. Chong, W. Liauw, J. Zhao, and D.L. Morris Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy Ann Surg 256 2 2012 Aug 342 349
8. K.G. Moons Criteria for scientific evaluation of novel markers: a perspective Clin Chem 56 4 2010 Apr 537 541
9. M.J. Proctor, D.S. Morrison, D. Talwar, and et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study Eur J Cancer 47 17 2011 Nov 2633 2641
10. T. Onodera, N. Goseki, and G. Kosaki Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients Nihon Geka Gakkai Zasshi 85 9 1984 Sep 1001 1005
11. S. Kusamura, D. Baratti, S. Virzi, and et al. Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres J Surg Oncol 107 4 2013 Mar 312 319
12. M. Deraco, D. Baratti, S. Kusamura, B. Laterza, and M.R. Balestra Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies J Surg Oncol 100 4 2009 Sep 15 321 328
13. D. Baratti, S. Kusamura, D. Nonaka, and et al. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) Ann Surg Oncol 15 2 2008 Feb 526 534
14. A. Weimann, M. Braga, L. Harsanyi, and et al. ESPEN guidelines on enteral nutrition: surgery including organ transplantation Clin Nutr 25 2 2006 Apr 224 244
15. R. Younan, S. Kusamura, D. Baratti, A.S. Cloutier, and M. Deraco Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy J Surg Oncol 98 4 2008 Sep 15 253 257
16. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 1987 373 383
17. B.M. Ronnett, C.M. Zahn, R.J. Kurman, M.E. Kass, P.H. Sugarbaker, and B.M. Shmookler Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei" Am J Surg Pathol 19 12 1995 Dec 1390 1408
18. S. Durrleman, and R. Simon Flexible regression models with cubic splines Stat Med 8 1989 551 561
19. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 4 1996 Feb 28 361 387
20. T.Z.H. Hothorn Unbiased recursive partitioning: a conditional inference framework J Comput Graph Stat 15 2006 651 674
21. M. Kanda, T. Fujii, Y. Kodera, S. Nagai, S. Takeda, and A. Nakao Nutritional predictors of postoperative outcome in pancreatic cancer Br J Surg 98 2 2011 Feb 268 274
22. I. Okada, A. Shirahata, H. Soda, and et al. Significance of Onodera's prognostic nutritional index for treating unresectable or recurrent colorectal cancer with chemotherapy Gan To Kagaku Ryoho 39 2 2012 Feb 231 235
23. P. Borelli, F.E. Barros, K. Nakajima, and et al. Protein-energy malnutrition halts hemopoietic progenitor cells in the G0/G1 cell cycle stage, thereby altering cell production rates Braz J Med Biol Res 42 6 2009 Jun 523 530
24. R. McQuellon, C. Gavazzi, P. Piso, D. Swain, and E. Levine Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): recommendations for care J Surg Oncol 98 4 2008 Sep 15 300 305
25. P. Royston, D.G. Altman, and W. Sauerbrei Dichotomizing continuous predictors in multiple regression: a bad idea Stat Med 25 1 2006 Jan 15 127 141
26. J.L. Koh, W. Liauw, T. Chua, and D.L. Morris Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy J Gastrointest Oncol 4 2 2013 Jun 173 181
27. K. Lohani, S. Shetty, P. Sharma, V. Govindarajan, P. Thomas, and B. Loggie Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment Ann Surg Oncol 21 5 2014 May 1441 1447
28. C.A. St Hill Interactions between endothelial selectins and cancer cells regulate metastasis Front Biosci (Landmark Ed 16 2011 3233 3251
29. H. Andreasson, W. Graf, P. Nygren, B. Glimelius, and H. Mahteme Outcome differences between debulking surgery and cytoreductive surgery in patients with Pseudomyxoma peritonei Eur J Surg Oncol 38 10 2012 Oct 962 968
30. S. Dayal, P. Taflampas, S. Riss, and et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved Dis Colon Rectum 56 12 2013 Dec 1366 1372